Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes
Clinical trial NCT05035368 · WITHDRAWN
Trial details
- NCT number
- NCT05035368
- Sponsor
- Dompé Farmaceutici S.p.A
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-30
- Primary completion
- 2023-06-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.